-
Biotech Veteran Pushes New Science And Regulatory Change9/1/2023
Ashvattha Therapeutics CEO Jeff Cleland hopes to bring hydroxyl dendrimer therapeutics to market for the first time, while also pushing for policy and regulatory change as an advocate for BIO.
-
Novo Nordisk Returns To Growth, With Growing Pains8/1/2023
Novo Nordisk’s return to growth is largely due to an explosion of demand for its anti-obesity products. However, challenges with supply and insurance coverage persist.
-
A Measure Of Improvement Needed8/1/2023
New and improved ways of measuring disease symptoms and responses to therapy must overcome established forms of measurement used for regulatory approval.
-
Vincerx Pharma: Finding Strength In Symbiosis8/1/2023
Ahmed Hamdy and Raquel Izumi are putting the lessons, hard knocks, and experiential wisdom they have gained over a decade in biotech to work at Vincerx.
-
I-MAK’s Quest To Trim The Biopharmaceutical Patent Thicket7/3/2023
I-MAK, a nonprofit focused on reforming the drug patent system, is bringing patients into the patent system to advocate against abuses that keep affordable drugs out of reach.
-
Civica Takes On Insulin Market, Opens Manufacturing Facility7/3/2023
With a new manufacturing plant opening in Virgina, Civica is poised to move into new product areas, including affordable insulin.
-
More Than A Seat At The Table7/3/2023
Bringing different perspectives together is important when debating industry policies, but the middle ground can still be allusive.
-
From Biggest Pharma To Rare Disease Start-Up6/1/2023
Martin Mackay’s journey from Pfizer executive to founding and leading a rare disease biotech is a reflection of the industry’s evolution from a small molecule powerhouse to multimodal biotech.
-
More Transparency, To A Point6/1/2023
New salary transparency laws are being enacted by a growing number of states, and more transparency is needed to address existing inequities. Is it possible to be too transparent?